A randomized phase II multicenter trial to explore efficacy of weekly intraperitoneal in comparison with intravenous paclitaxel administered immediately after gastrectomy to the patients with high risk of peritoneal recurrence: final results of the INPACT trial

被引：0
|
作者：
Naoto Takahashi
Mitsuro Kanda
Takaki Yoshikawa
Nobuhiro Takiguchi
Kazumasa Fujitani
Katsufumi Miyamoto
Yuichi Ito
Osamu Takayama
Motohiro Imano
Norio Mitsumori
Junichi Sakamoto
Satoshi Morita
Yasuhiro Kodera
机构：
[1] Kashiwa Hospital,Department of Surgery, Jikei University School of Medicine
[2] Nagoya University Graduate School of Medicine,Department of Gastroenterological Surgery (Surgery II)
[3] Kanagawa Cancer Center,Department of Gastrointestinal Surgery
[4] Chiba Cancer Center,Division of Gastroenterological Surgery
[5] Osaka Prefectural General Medical Center,Department of Surgery
[6] Hyogo Prefectural Awaji Medical Center,Department of Surgery
[7] Aichi Cancer Center Hospital,Department of Gastroenterological Surgery
[8] Itami City Hospital,Department of Surgery
[9] Kinki University,Department of Surgery, Faculty of Medicine
[10] Jikei University School of Medicine,Department of Surgery
[11] Tokai Central Hospital,Department of Biomedical Statistics and Bioinformatics
[12] Kyoto University Graduate School of Medicine,undefined
来源：
Gastric Cancer | 2018年 / 21卷
关键词：
Gastric cancer; Intraperitoneal administration; Paclitaxel; Peritoneal metastasis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1014 / 1023
页数：9
相关论文
共 43 条
  • [1] A randomized phase II multicenter trial to explore efficacy of weekly intraperitoneal in comparison with intravenous paclitaxel administered immediately after gastrectomy to the patients with high risk of peritoneal recurrence: final results of the INPACT trial
    Takahashi, Naoto
    Kanda, Mitsuro
    Yoshikawa, Takaki
    Takiguchi, Nobuhiro
    Fujitani, Kazumasa
    Miyamoto, Katsufumi
    Ito, Yuichi
    Takayama, Osamu
    Imano, Motohiro
    Mitsumori, Norio
    Sakamoto, Junichi
    Morita, Satoshi
    Kodera, Yasuhiro
    GASTRIC CANCER, 2018, 21 (06) : 1014 - 1023
  • [2] A Randomized Phase II Trial to Test the Efficacy of Intra-peritoneal Paclitaxel for Gastric Cancer with High Risk for the Peritoneal Metastasis (INPACT Trial)
    Kodera, Yasuhiro
    Imano, Motohiro
    Yoshikawa, Takaki
    Takahashi, Naoto
    Tsuburaya, Akira
    Miyashita, Yumi
    Morita, Satoshi
    Nakao, Akimasa
    Sakamoto, Junichi
    Sasako, Mitsuru
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (02) : 283 - 286
  • [3] A Randomized Phase II/III Trial of 3 Weekly Intraperitoneal versus Intravenous Carboplatin in Combination with Intravenous Weekly Dose-dense Paclitaxel for Newly Diagnosed Ovarian, Fallopian Tube and Primary Peritoneal Cancer
    Fujiwara, Keiichi
    Aotani, Eriko
    Hamano, Tetsutaro
    Nagao, Shoji
    Yoshikawa, Hiroyuki
    Sugiyama, Toru
    Kigawa, Junzo
    Aoki, Daisuke
    Katsumata, Noriyuki
    Takeuchi, Masahiro
    Suzuki, Mitsuaki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (02) : 278 - 282
  • [4] An evaluation of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy on patients with peritoneal carcinomatosis: Final results of a phase II prospective and randomized clinical trial
    Li, Y.
    Yang, X.
    Yang, G.
    Zhou, Y.
    Yonrmura, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] Intraperitoneal and intravenous paclitaxel plus S-1 versus intravenous paclitaxel plus S-1 in gastric cancer patients with peritoneal metastasis: Results from the multicenter, randomized, phase 3 DRAGON-01 trial.
    Yang, Zhongyin
    Shi, Zheng
    Lu, Sheng
    Shi, Min
    Nie, Mingming
    Chen, Jian
    Wu, Dan
    Mou, Yiping
    Xu, Yunyun
    Wang, Yanong
    Liu, Xiaowen
    Cao, Hui
    Gu, Jiayi
    Yu, Jiren
    Liu, Kai
    Liu, Xinchun
    Zhang, Jun
    Yin, Kai
    Zhu, Zhenggang
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 327 - 327
  • [6] A randomized phase 3 trial of intraperitoneal versus intravenous carboplatin with dose-dense weekly paclitaxel in patients with ovarian, fallopian tube, or primary peritoneal carcinoma (a GOTIC-001/JGOG-3019/GCIG, iPocc Trial)
    Fujiwara, Keiichi
    Nagao, Shoji
    Yamamoto, Kouji
    Tanabe, Hiroshi
    Okamoto, Aikou
    Takehara, Kazuhiro
    Saito, Motoaki
    Fujiwara, Hiroyuki
    Tan, David
    Adachi, Sosuke
    Yamaguchi, Satoshi
    Kikuchi, Akira
    Hirasawa, Takeshi
    Yokoi, Takeshi
    Nagai, Tomonori
    Satoh, Toyomi
    Kamiura, Shoji
    Fujishita, Akira
    Hirasawa, Takeshi
    Yokoi, Takeshi
    Nagai, Tomonori
    Satoh, Toyomi
    Kamiura, Shoji
    Fujishita, Akira
    Chan, Karen
    Sykes, Peter
    Olawaiye, Alexander
    Ryu, Sang-Young
    Wong, Wai Loong
    Matsumoto, Takashi
    Hasegawa, Kosei
    Enomoto, Takayuki
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S49 - S50
  • [7] A randomized, multicenter phase III trial comparing regimens of doxorubicin plus cyclophosphamide followed by paclitaxel or doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for patients with high risk breast cancer
    Loesch, D
    Greco, FA
    O'Shaughnessy, J
    Asmar, L
    Senzer, NN
    Burris, HA
    Hainsworth, JD
    Vukelja, S
    Sandbach, J
    Holmes, F
    Sedlacek, S
    Lindquist, D
    Pippen, J
    Olivares, J
    Boehm, KA
    Zhan, F
    Robert, N
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S16 - S17
  • [8] A combination chemotherapy of weekly paclitaxel and doxifluridine (5′-DFUR: an intermediate metabolite of capecitabine) in patients with unresectable or recurrent gastric cancer in an outpatient setting. Final results of a multicenter phase II trial
    Yoshino, S.
    Nishimura, T.
    Hazama, S.
    Oka, M.
    Ozasa, H.
    Shimizu, R.
    Furuya, T.
    Fukuda, S.
    Satoh, T.
    Hara, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma The OCTOPUS Multicenter, Phase 2, Randomized Clinical Trial
    Banerjee, Susana
    Giannone, Gaia
    Clamp, Andrew R.
    Ennis, Darren P.
    Glasspool, Rosalind M.
    Herbertson, Rebecca
    Krell, Jonathan
    Riisnaes, Ruth
    Mirza, Hasan B.
    Cheng, Zhao
    McDermott, Jacqueline
    Green, Clare
    Kristeleit, Rebecca S.
    George, Angela
    Gourley, Charlie
    Lewsley, Liz-Anne
    Rai, Debbie
    Banerji, Udai
    Hinsley, Samantha
    McNeish, Iain A.
    JAMA ONCOLOGY, 2023, 9 (05) : 675 - 682
  • [10] Final survival results from a multicenter, randomized phase II trial of intravenous paclitaxel plus FOLFOX (ivPOF) and/or intraperitoneal paclitaxel plus FOLFOX (ipPOF) versus mFOLFOX6 as first-line treatment of advanced gastric cancer (AGC): SYLT/FNF 004.
    Zhao, Shen
    Lin, Rongbo
    Fan, Nan-Feng
    Chen, Yigui
    Li, Xiaofeng
    Lin, Peicheng
    Chen, Wujin
    Fang, Wenzheng
    Zhu, Jinfeng
    Li, Hui
    Liu, Jie
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345